---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-037547"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:38.527878+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028

## Summary
- Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.
- Trial is 26-week, randomized, dose-ranging, double-blind, placebo-controlled, once-daily dosing.
- Primary efficacy endpoint: change from baseline in forced vital capacity (FVC) at week 26.
- Trial design informed by regulatory feedback and completed Phase 1 data; completion expected June 2028.
- No financial guidance or capital structure changes included in this filing.

## SEC filing metadata
- accession: 0001437749-25-037547
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925037547/0001437749-25-037547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925037547/ctnm20251204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-037547
- JSON: https://secwatch.observer/filing/0001437749-25-037547.json
- Plain text: https://secwatch.observer/filing/0001437749-25-037547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.